Mobile app to help cancer patients with advance care planning

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of a mobile health application called Planning Advance Care Together (PACT) designed to assist cancer patients in discussing and planning their advance care preferences with family and healthcare providers. Participants are randomly assigned to either use the PACT app or receive standard care without modifications. The study aims to enhance patient engagement in advance care planning by incorporating their social networks into the process. Follow-up assessments are conducted at 3 and 6 months post-intervention to evaluate outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* PATIENT: Diagnosis of poor prognosis advanced cancer defined as locally advanced or metastatic solid cancer and/or disease progression following at least first line systemic therapy and/or relapsed or refractory hematologic cancer.
* PATIENT: Have internet access through a computer or a mobile device; the principal investigator (PI) will ensure that those who have access to a computer or mobile device have access to a computer or mobile device with internet access to ensure they can complete study procedures.
* PATIENT: The ability to provide informed consent.
* PATIENT: Identification of a loved support person if one is available; patients who are unable to identify a support person willing to participate with them will be allowed to continue in the study on their own.
* PATIENT: 18 years of age or older.
* SUPPORT PERSON: The person (family member or friend) whom the patient indicates being a support person.
* SUPPORT PERSON: English speaking.
* SUPPORT PERSON: 18 years of age or older and able to provide informed consent.
* PROVIDER: Current clinical practice and/or research with advanced cancer patients.
* PROVIDER: A history of 3+ years working with advanced cancer patients.
* PROVIDER: 18 years of age or older. Providers across disciplines (e.g., social work, oncology) will be enrolled.

Exclusion Criteria:

* PATIENT: Not fluent in English.
* PATIENT: Severely cognitively impaired (as measured by Short Portable Mental Status Questionnaire scores of \>= 6) to be delivered by trained study research staff during screening.
* PATIENT: Too ill or weak to complete the interviews (as judged by the interviewer).
* PATIENT: Currently receiving hospice at the time of enrollment.
* PATIENT: Children and young adults under age 18.

Where it's running

• Fred Hutch/University of Washington Cancer Consortium
  Seattle, Washington, United States Recruiting
• Northwell Health
  Manhasset, New York, United States Not yet recruiting
• Mount Sinai Hospital
  New York, New York, United States Active not recruiting
• NYP/Weill Cornell Medical Center
  New York, New York, United States Not yet recruiting

Study contacts

• Principal investigator: Megan J Shen, PhD — Fred Hutch/University of Washington Cancer Consortium
• Study coordinator: Claudia De Los Santos, B.S.
• Email: cdelossa@fredhutch.org
• Phone: 206-667-1565

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining two anticancer drugs for treating advanced gastric and gastroesophageal junction cancers

  This study is testing a new combination of two cancer drugs to see if they can help people with advanced HER2-positive gastric or gastroesophageal junction cancers feel better and live longer.

  Recruiting Phase 1 National Cancer Institute (NCI) · Houston, Texas · NCT06364410

• Monitoring T Cell Responses in Cancer Patients Receiving Anti-PD-1 Therapy

  This study is trying to see how T cells in the blood can help doctors understand how well anti-PD-1 therapy works for people with melanoma, lung cancer, and other cancers.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06075524

• Targeted therapy for advanced solid tumors based on genetic testing

  This study is testing whether matching patients with advanced solid tumors to specific treatments based on their genetic makeup can improve their outcomes when standard options have failed.

  Recruiting at 437 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 483 other locations · NCT05564377

• Personalized vaccine combined with pembrolizumab for advanced solid tumors

  This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT05269381

• Treatment of advanced solid tumors with larotrectinib for NTRK gene amplification

  This study is testing if a new drug called larotrectinib can help people with advanced solid tumors that have a specific gene change called NTRK amplification.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04879121

• Avapritinib for treating advanced solid tumors with specific mutations

  This study is testing if a new drug called avapritinib can help people with advanced solid tumors that have specific mutations feel better and live longer after other treatments haven't worked.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04771520

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.